• OPEN AN ACCOUNT
Indian Indices
Sensex
74,529.08 -329.91
( -0.44%)
Global Indices
Nasdaq
52,073.35 369.71
(0.72%)
Dow Jones
7,785.28 113.78
(1.48%)
Hang Seng
65,040.24 903.99
(1.41%)
Nikkei 225
10,723.15 -15.86
(-0.15%)
Forex
USD-INR
95.99 0.12
(0.12%)
EUR-INR
110.24 0.24
(0.22%)
GBP-INR
128.54 0.36
(0.28%)
JPY-INR
0.61 0.00
(-0.53%)

EQUITY - MARKET SCREENER

Oil & Natural Gas Corpn Ltd
Industry :  Oil Drilling / Allied Services
BSE Code
ISIN Demat
Book Value()
500312
INE213A01029
263.722637
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ONGC
7.07
296139.77
EPS(TTM)
Face Value()
Div & Yield %
33.31
5
3.08
 

Indoco Remedies soars after Goa plant clears UK MHRA cGMP inspection
Sep 10,2026
The inspection of the facility, which manufactures solid oral dosage forms, was conducted from 7 September 2026 to 9 September 2026. The UK MHRA's current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations, indicating compliance with the regulator's applicable manufacturing standards.

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. It develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc.

The company reported a consolidated net profit of Rs 64.99 crore in Q1 FY27 as against a net loss of Rs 35.79 crore in Q1 FY26. Revenue from operations rose 8.43% year on year to Rs 466.22 crore in the first quarter of FY27 from Rs 430.86 crore in the corresponding quarter last year.